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Abstract 
Background: Women are at higher risk to suffer from depressive symptoms or 
develop major depression. It is suggested that stages of hormonal fluctuation during a 
women’s lifespan runs parallel with an increased risk for mood disturbances. One of 
these stages of interest is the menopausal transition, also called the perimenopausal 
stage: the last stage of the reproductive lifespan in a women’s life.  
Aim: The purpose of this meta-analysis was to synthesize the existing studies of the 
relationship between menopausal stage and depression. 
Method: Based on the PRISMA statement a systematic literature research was 
performed using PubMed. In total eleven studies on perimenopausal stage and 
depressive symptoms and two perimenopause and risk of depression were selected. 
The results of group comparisons were summarized using the log odds ratio and its 
estimated standard error and by using the reported group mean and the number of 
participants per group. 
Results: Results confirm the expectation that perimenopausal women were at 
significantly increased risk of depression and to report higher levels of depressive 
symptoms as compared to premenopausal women.  
Conclusion: The perimenopause is a time of a significant increased risk to have a first 
onset depression, and menopausal women are found to suffer more from depressive 
symptoms when compared to premenopausal women. This meta-analysis adds body 
to the research of the link between reproductive aging and depression, with the 
menopausal transition as a significant stage. 
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1. Introduction 
More than 350 million people of all ages suffer from depression worldwide, it affects 
between 4 and 14% of all people at any point in their lives (Prince et al., 2007). 
Depression is the main cause of disability on a mundial scale; thereby it contributes to 
the worldwide burden of disease and health costs (Almeida et al., 2014; Depression  
Factsheet N°369, 2012). In a factsheet of The World Health Organisation (WHO) 
(2012), it is report indicated that 31.7% of the population lived with disabilities due to 
neuropsychiatric conditions, of which the main contributor is depression, with 11.8% 
(Prince et al., 2007). A meta-analysis of 15 population-based studies, reported that 
depression is linked to subsequent all-cause mortality with a pooled Odds Ratio (OR) 
of 1.7 (95% CI 1∙5–2∙0) (Prince et al., 2007). At its most severe, depression may lead 
to suicide what results in an estimated one million deaths every year 
(http://WHO.com).  
 There is a considerable change in the gender proportions of depression after 
puberty. The prevalence of depression is consistently higher in women across the 
reproductive lifespan, from “menarche” until “menopause” and a female to male ratio 
of 2 - 3 : 1 has been found (http://WHO.com; Almeida et al., 2014; Piccinelli & 
Wilkinson, 2000; Kessler et al., 1993; Soares et al., 2003). In a large-scale research by 
Kessler and colleagues (1994) the lifetime prevalence’s of major depressive episodes 
are found to be 21,3% in women against 12,7% in men. Even after controlling for 
social and environmental factors the rate of depression is much higher in women 
(Piccinelli & Wilkinson, 2000). Additionally, increasing attention seems to occur for 
the role of gender differences in health and the medical science (Padgeit, 1997). These 
findings led to studies investigating the relation between depression and womanhood 
and to clarify the suspected link. The relationship between depression and 
reproductive aging has been found in women, and perimenopausal women appear to 
be at a higher risk in comparison to premenopausal women (Weber et al., 2013).  
 Through systematic review and meta-analysis this study aims to summarize 
and examine the risk and prevalence in perimenopausal women (menopausal women) 
to become depressed or to experience depressive symptoms. The definition of 
perimenopause, as applied in this study and following the criteria of the Stages of 
Reproductive Aging Workshop (STRAW), will be described (paragraph 1.2), after 
which the role of sex hormones during reproductive aging and the link of these 
hormones in developing depression will be explained (paragraph 1.3). Psychosocial 
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and physical characteristics of menopausal women will be described (paragraph 1.4), 
after which research towards the link between perimenopause and depression will be 
focused on. The method (paragraph 2) of this literature research is based on the 
PRISMA guidelines and the meta-analysis will be focusing on depressive symptoms 
and depression in perimenopausal- (and postmenopausal) women compared to 
premenopausal women. Finally, findings and recommendations will be described in 
the discussion, after which the limitations and conclusion of this study will be given.  
At first the importance of this study will be illustrated by prevalence of depression 
and depressive symptoms in perimenopausal women in particular what led to 
perimenopausal women as group of interest in this study.  
 
1.1 Perimenopause: a risk for depression 
It has been found that women are more vulnerable when it comes to mood 
disturbances such as depression during different stages over a lifespan (Almeida et al., 
2014). These periods are strongly linked to different stages in reproductive aging in 
which hormonal changes play a role. Considerable stages for mood disturbance or 
depressed mood are the premenstrual phase of the menstrual cycle, the postpartum 
period, and perimenopause (Borrow & Cameron, 2014; Douma et al., 2005; Vivian-
Taylor, 2014).  
 
 
 Figure 1. Simplification of estrogen (in percentages) fluctuations across a women’s life span (Almeida 
et al., 2014).  
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As shown in figure 1, the highest prevalence of depression has been found during the 
perimenopausal stage (Almeida et al., 2014), a recently published systematic-review 
confirmed this finding (Weber et al., 2014). An increase is seen in the number of 
clinically significant depressive symptoms during the years that overlap with the 
menopausal transition, during perimenopause, 15-30% of all women suffer from 
depressive symptoms (Almeida et al., 2014). These findings suggest that the 
perimenopausal stage is a time for increased vulnerability for developing depression. 
Evidence shows that perimenopausal women are at a higher risk to develop depressive 
symptoms or even a depression or a depressive episode, in particular among women 
with a history of mood disorders, this has been suggested by large longitudinal cohort 
studies (Schmidt et al., 2004; Cohen et al., 2006; Soares et al., 2001; Dennerstein et 
al., 2000; Joffe et al., 2002; Ladd et al., 2005; Harlow et al., 2003).  
 
1.2 STRAW: Stages of Reproductive Aging Workshop 
In 2001, the Stages of Reproductive Aging Workshop (STRAW) was held. The 
purpose of the workshop was to create an objective staging system for healthy female 
reproductive aging (Soules et al., 2001). In 2011 a follow-up workshop was held; 
“STRAW + 10” reviewed scientific progression and updated the STRAW criteria. 
The reviewed and improved version of the STRAW criteria includes the advanced 
scientific knowledge of hypothalamic pituitary and ovarian function that changes 
critically before and after the final menstrual period. STRAW proposed a 
nomenclature and a staging system for ovarian aging including the menstrual and 
qualitative hormonal criteria to define each stage (Soules et al., 2001; Harlow et al., 
2012). Divisions made between the stages are based on the duration of the menstrual 
cycles, endocrine level, physical symptoms, fertility and uterine/ovarian anatomy 
(Soules et al., 2001). Each of the stages that are defined by STRAW is divided into 
“sub” stages. The “menopausal transition” is also called “perimenopause”, starting 
two years before “postmenopause” and is the last phase in the reproductive years in a 
women’s life (Harlow et al., 2012; Benazzi, 2000). The staging system is only 
applicable to naturally menopausal women. “STRAW +10” has defined the 
perimenopausal stage using the terms “early menopausal transition” and “late 
menopausal transition”. The “early menopausal transition” is determined by an 
increased variability in menstrual cycle length.  
 7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The stages and their criteria by STRAW (Soules et al., 2001). 
 
The “late menopausal transition” is determined by longer periods between the 
menstruations, and marked by the occurrence of amenorrhea of sixty days or longer 
and is estimated to last one to three years during which the menstrual cycles are 
increasingly variable in cycle length. It is also characterized by fluctuations in 
hormonal levels and a growing absence of ovulation. Menopausal symptoms, such as 
vasomotor symptoms, are to be expected to occur during this stage. 
This objective staging system provides a framework in which clear criteria contribute 
to improvement in systematic research in aging women. Studies intended to increase a 
better understanding of a possible link between reproductive stages and depression 
may be enhanced in quality using the STRAW criteria (Harlow et al., 2012). 
Therefore, in order to strengthen the validity and reliability of this study, the STRAW 
criteria are maintained. 
 
1.3 Reproductive aging: a link between sex hormones and depression 
STRAW has linked the decrease in ovarian estrogens and progesterone and an 
increase in serum Follicle Stimulating Hormone (FSH) to reproductive aging. In 
perimenopausal women lower levels of estrogens and a higher level of FSH have been 
found as compared to premenopausal women. Women are considered to be in the 
transitional phase, from reproductive to a non-reproductive life stage, when increased 
FSH levels lead to observable irregularities in the menstrual cycle. The menopausal 
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transition is characterized by fluctuations in sex steroid levels. Declining estrogen, as 
seen in perimenopausal women, is associated with an increased risk of depressive 
symptoms and depressive disorders (Schmidt, 2005; Weber et al. 2014; Soules et al., 
2001; Mauas et al., 2014; Vivian-Taylor & Hickey, 2014). Douma and colleagues 
(2005) indicated that significant mood disturbances are correlated to withdrawal of 
estrogen as well as fluctuations in estrogen levels in women. In summary, research 
indicates a significant link between sex hormones and depression. More specifically, a 
strong relationship has been found between estrogen and mood disorders in women 
(Borrow & Cameron, 2014). Sex hormones as a treatment for depression have also 
been studied. A double blind randomized placebo-controlled trial demonstrated that 
estrogen therapy improves clinical depression significantly in perimenopausal women 
(Soares et al., 2001). The positive effect of hormonal treatment in perimenopausal-
depressed women is a step forward in the fight against this mental illness. 
Additionally, it confirms the link between sex hormones and depression and indicates 
a heightened risk for depressive symptoms in perimenopausal women (Borrow & 
Cameron, 2014). These findings underscore a possible relation between depression 
and the menopausal transition. Other factors for perimenopausal woman suffering 
from depressive symptoms, next to this biological explanation, might also play a role 
and are presented in the next paragraph. 
 
1.4 Physiological and psychosocial changes during perimenopause 
The menopausal transition affects all ageing women with intact ovaries. This period 
in a women’s life is marked by physiological and psychosocial changes. The 
menopausal transition starts at around the age of forty-seven and may last from four to 
seven years. This period, also known as “menopause”, is the final stage of the 
reproductive years in a women’s life. When women have gone through this period in 
life, she is considered to be “postmenopausal” (Almeida et al., 2014). Many 
perimenopausal women suffer from vasomotor symptoms (VMS), such as hot flushes 
and night sweats, but also sleep disturbances, remodelling of body shape, vaginal 
dryness and dyspareunia, decreased libido, urinary symptoms, muscle and joint pains 
and onset of chronic illnesses such as diabetes and hypertension are common among 
perimenopausal women (Dratva et al., 2009; McKinlay et al., 2008; Guthrie et al., 
2005; Vivian-Taylor & Hickey, 2014). Brown and colleagues (2009) revealed that 
elevated CES-D (Center for Epidemiologic Studies Depression) score in women 
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during midlife is associated with menopausal symptoms even after controlling for 
menopausal stage, physical activity level, smoking behaviour and self-reported health 
status. Studies investigated the role of vasomotor symptoms, due to menopause, in 
developing depressive mood. Findings suggest that the chance of being depressed 
increased 15% for every one-unit increase in climacteric physiological symptoms (Lu 
et al., 2009). Opperman and colleagues (2012) found that vasomotor symptoms were 
more prevalent in perimenopausal women than during the postmenopause. In 
perimenopausal woman 76.7% reported hot flashes, 78.9 % irritability and 53.3% 
night sweats.  
 Not only physical changes may play a role in the discomforts women 
experience during this period. Psychosocial distress often occurs during this stage in a 
women’s life. For example: children leave home ( “empty nest syndrome”), getting a 
divorce, or a parent who becomes ill or passes. Additionally, a negative attitude 
towards aging may play a role in developing depressive symptoms or a depression in 
menopausal women (Vivian-Taylor & Hickey, 2014; McKinlay et al., 2008). 
Concordantly, negative characteristics of the menopausal transition, such as 
psychological stressors and physiological discomforts, may contribute to the 
development of depressive symptoms or even a depressive episode. Different 
explanations for the occurrence of depressive symptoms during menopausal transition 
are explored, yet still no compelling theory about it has been formulated (Kaufert et 
al., 1998; Avis & McKinlay, 1991). 
 In conclusion, the menopausal transition runs parallel to midlife: a time of 
social and personal change. The increased vulnerability among women to develop a 
depression during this period may be explained through health issues, biological 
changes and psychological stress evoked by major life events. This wide range of 
explanations has led to a myriad of research projects examining the relation between 
depression and reproductive aging and can be approached in a bio-psychosocial way.  
 
1.5 Research towards menopausal transition and depression 
Many studies have been conducted to assess the relation between menopausal 
transition and depressed mood. Among perimenopausal women treated in menopausal 
clinics, high rates of depressive symptoms are observed. These outcomes are 
confirmed by cross-sectional longitudinal population based studies in which 
perimenopausal women are to be found at high risk for mood disturbances (Soares et 
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al., 2001). Bromberger and his colleagues (2007) performed an epidemiological study 
using data that was extracted from a large-scale study towards women’s health, 
SWAN (The Study of Women's Health Across the Nation). The SWAN is a 
prospective midlife study in the United States. This study reports that nearly 25% of 
the women experience clinically significant depressive symptoms during the 
menopausal transition. Depressive disorders were twice as likely among 
perimenopausal women. Interestingly, among postmenopausal women depression was 
found to be four times more common in comparison to premenopausal women.  
A longitudinal prospective cohort found that perimenopausal women are at an 
increased risk to develop a first onset of depression when compared to premenopausal 
women (Cohen et al., 2006). Perimenopausal women without a history of depression 
are two to four times more likely to report depressed mood compared with 
premenopausal women (Hickey et al., 2012; Soares et al., 2007). Schmidt and 
colleagues (2004) found that women with a history of depression where 5 times more 
likely to suffer from recurrence of depression during menopausal transition.  
 However, not all conducted studies regarding this topic show the link between 
menopausal status and depression. Some epidemiologic research has shown that the 
majority of women does not develop a major depression during the perimenopause, 
which suggests that the menopausal transition alone does not increase the 
vulnerability for clinically significant depressive symptoms (Cohen et al., 2006; 
Hickey et al., 2012; McKinlay et al., 1987; Matthews et al., 1990). 
 Clearly, many studies have been conducted to clarify the link between the 
perimenopausal stage and depression and depressive symptoms, but a definite relation 
is still absent. The present study aims to summarize all valuable data obtained from 
preliminary research in order to give an overview of information by executing a meta-
analysis. It is important to acquire knowledge of the prevalence of depressive 
symptoms and depression in this specific group of women. Firstly, it contributes to 
cost effective prevention and health care. Moreover, it helps to improve the quality of 
healthcare and treatment, which contributes to the quality of life and better health for 
women in this phase of life (Avis et al., 2003; Bromberger et al., 2007). The meta-
analysis of the present study aims to clarify the discrepancy between reported data on 
the relation between depression and women in the perimenopausal period based on 
previous research. Interesting data concerning high prevalence for depression and 
postmenopausal women was also found. However, limited consideration is given to 
 11 
this cohort, since this study is mainly interested in the transitional period and it’s 
relation with depression. Firstly, it is expected that the results will support the 
hypothesis that perimenopausal women have a higher risk of experiencing depressive 
symptoms than premenopausal women. Secondly, it is hypothesized that 
perimenopausal women experience more depressive symptoms than premenopausal 
women. Lastly, it is hypothesized that perimenopausal women are at higher risk for 
depression than premenopausal women.  
 
2. Method 
2.1 PRISMA guidelines 
This study is focused on giving an overview on data derived from research that 
investigates the prevalence and risk of depressive symptoms and depression among 
perimenopausal women and aims to draw a generalizable conclusion based on a clear 
and structured literature study. The PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) statement is used to monitor the quest for 
reliability and quality (Moher et al., 2009). The PRISMA Statement is based on 
definitions used by “The Cochrane Collaboration” and aims to improve reporting of 
systematic reviews and meta-analysis.  
 
2.2 Search and selection of relevant studies 
This meta-analysis is based on peer-reviewed literature found in the databases Web of 
Science, PubMed and Google Scholar. The following search terms were used: “Major 
depression” and “Major depressive disorder” were the two key terms used in 
combination with: “Menopause”, “Perimenopause”, “Climacteric”, “Female 
hormones”. All combinations and key terms were also used with asterisks (*) in order 
not to miss any usable data. The separated keywords that were used were: 
“Perimenopausal depression”, “Menopausal depression”, “Climacteric depression”, 
“Involutional depression”. In the data research the following restrictions were applied: 
“Humans”, “English” and “Female”.  
All studies where screened for eligibility based on the following inclusion criteria: (1) 
STRAW defined perimenopausal women (see figure 2), and pre- and/or 
postmenopausal women as reference group, (2) both depression and depressive 
symptoms needed to be measured by validated questionnaires, such as the DSM IV 
criteria to diagnose a depression and BDI (Kuhner et al., 2007) to measure depressive 
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symptoms, (3) the last required inclusion criteria was the availability of an odds ratio 
and 95% confidence interval or the number of participants per group with the odds 
ratio and standard error. In case of missing data, adequately reported raw data were 
used to calculate the necessary data. Studies that obtained participants from a clinical 
setting were excluded to enlarge generalizability. 
 
2.3 Data extraction 
Data extraction was independently conducted by two students (from the University of 
Leiden); each identified the required statistics from the individual papers and agreed 
on the obtained data. The odds ratio (and confidence interval of 95%) where extracted 
for depression and depressive symptoms by the STRAW defined menopausal stages 
with pre- or postmenopausal women as reference group for perimenopausal women 
and pre- and perimenopausal women as reference group for postmenopausal women.  
For depressive symptoms, also the number of participants in each menopausal group, 
the mean score for depressive symptoms with its standard error, was independently 
extracted for each group. When studies reported data, adjusted for relevant covariates, 
such as history of depression, the adjusted data was extracted.  
 
2.4 Statistical analysis 
In order to compromise the extracted data, “Comprehensive Meta-Analysis 2.0” 
(CMA 2.0) was used, in which three separate data sets where generated: the risk for a 
depression among perimenopausal women and two data sets in which depressive 
symptoms were analysed. The results of the group comparisons (perimenopausal, 
premenopausal or postmenopausal and postmenopausal women) were summarized by 
using the log odds ratio and its estimated standard error derived from the reported 
95% confidence interval to calculate the odds ratio; or by the number of participants 
in each group and its mean score of depressive symptoms to calculate the effect size 
and Hedge’s g.  By means of a forest plot we will illustrate different individual studies 
included in the meta-analysis and graphically display the estimated result of the 
summarised data (Lalkhen & McCluskey, 2008). 
 Random-Effect (RE) models were used to estimate the overall summarized log 
odds ratios and Hedge’s g across the different studies (Comprehensive Meta-Analysis 
2.0), since RE analyses reduce the likelihood of committing a Type I error and can be 
regarded as a more “conservative” than the Fixed-Effect model (Cohn and Becker, 
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2003). Besides, by using the RE model we take possible heterogeneity of obtained 
data from the individual studies in account. The RE model seems to give a more 
reliable and realistic representation of the summarised data (Cumming, 2012).  
We evaluated the heterogeneity of the effect sizes by means of the Q statistic and the 
I² statistic in order to determine whether there are differences underlying the results of 
the included studies (heterogeneity). The Q statistic assesses the variability between 
study means. In order to quantify heterogeneity we calculated the I², which describes 
the percentage of total variation across the included studies that is due to 
heterogeneity rather than chance (Cumming, 2012). The I² is expressed as a 
percentage, 0.25, 0.5, 0.75, indicating low, moderate and high heterogeneity 
respectively (Higgins et al., 2003). Lastly, publication bias was assessed by means of 
Egger’s test and a funnel plot (Duval & Tweedie, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
3. Results 
 
3.1 Study selection 
 
In figure three, a flowchart represents the selection process of the included studies 
based on the maintained PRISMA guidelines (Moher et al., 2009). 
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searching and reference review 
n = 3245 
 
Screening on title and reading the 
abstract 
n = 870 
Assessment of full- texts for eligibility 
n =17 
Excluded full-text articles 
n = 853 
 
Reviews:    n = 304 
Meta-analysis:    n = 1 
Lack of data:    n = 23 
Not eligible     n = 504 
Based on in/exclusion criteria 
Clinical setting: n = 21 
 
 
Inclusion of eligible articles  
n = 16 
Studies included in 
meta-analysis: 
 
Depressive 
symptoms in 
perimenopausal 
women; based on 
mean differences 
 
n = 5* 
Studies included in 
meta-analysis: 
 
Depressive 
symptoms in 
perimenopausal 
women; based on  
Log odds  
(CI 95%) 
n =10* 
 
Studies included in 
meta-analysis: 
 
Diagnosis major 
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n = 2 
* = Includes one overlapping study: Timur & Sahin, 2010 
Figure 3. Flowchart illustrating included studies in different phases of the systematic review. 
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3.2 Depressive symptoms  
3.2.1 Individual studies 
Figure 3 shows a flowchart of the studies that where eligible to include in this meta-
analysis. In total, fifteen studies were included to analyse the effect of the 
perimenopausal period on depressive symptoms of which two made a difference 
between early and late menopausal transition (Freeman et al., 2004; Bromberger et al., 
2010). These two studies are separately analysed to prevent the results of the analysis 
from bias. Eleven studies reported the odds ratios and confidence intervals and five 
studies presented data from which the Hedge’s g effect size could be calculated; one 
of these studies could be included in both analyses (Timur & Sahin, 2010). Study 
characteristics (such as study design, population, depression questionnaire and 
number of participants) of the included studies are presented appendix 1, 2 and 3. 
Since not all studies reported the same study characteristics some data is missing in 
the tables.  
All of the included studies, excluded women with unnatural menopause (e.g., due to 
hysterectomy or premature menopause), following the STRAW criteria. Besides, only 
few of the studies maintained other exclusion criteria. Only three of the studies 
excluded women with mental illness (Cheng et al., 2008; Lu et al.,2009; Danaci et al., 
2003), and two studies excluded women using hormonal replacement therapy and oral 
contraceptive pill (Danaci et al., 2003; Dennerstein et al., 2004). Only Gallicchio and 
colleagues (2007) adjusted for: marital status, menopausal symptoms, smoking status, 
physical activity and self reported health. Opperman and colleagues (2012) controlled 
for skin colour and education.  
 
3.2.2 Depressive symptoms and reproductive stages: Analysing Odds ratio and 
Confidence Interval  
The results of the individual studies and the overall odds ratio of depressive 
symptoms in perimenopausal women are graphically displayed in a forest plot. Figure 
3.1 shows the results with premenopausal women as reference group, figure 3.2 
displays the results of the odds ratio with postmenopausal women as reference group 
and figure 3.3 shows the odds ratio between post- and premenopausal women.  
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Figure 3.1 Forest plots of analysis peri- vs. premenopausal women 
 
Figure 3.2 Forest plots of analysis peri- vs. postmenopausal women 
 
 
Figure. 3.3 Forest plots of analysis post- vs. premenopausal women
 
 
Table 1 shows an overview of the found odds ratio (CI) and p-values. In the meta-
analysis, the odds of experiencing depressive symptoms that indicate a clinical 
depression increased by 1.69  (CI = 1.28, 2.22; p < 0.001) in perimenopausal 
compared to premenopausal women, indicating a significant increase. When 
comparing early- and late perimenopausal women to premenopausal women, the odds 
of having depressive symptoms increased by 1.35 (CI = 1.15, 1.57) and 1.69 (CI = 
1.32, 2.18) respectively. Both calculated odds ratios indicate significant risk increases 
Model Study name Comparison Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Cohen et al., 2006 peri vs pre 1,800 1,006 3,220 1,981 0,048
Gallicchio et al., 2007 peri vs pre 1,030 0,662 1,604 0,131 0,896
Joffe et al., 2002 peri vs pre 2,125 1,039 4,347 2,066 0,039
Lu et al., 2009 peri vs pre 1,246 0,642 2,417 0,651 0,515
Opperman et al., 2012 peri vs pre 2,861 1,466 5,581 3,082 0,002
Timur et al., 2010 peri vs pre 2,061 1,272 3,337 2,939 0,003
Yen et al., 2009 peri vs pre 1,700 0,856 3,375 1,516 0,129
Random 1,686 1,283 2,215 3,745 0,000
0,01 0,1 1 10 100
Favours A Favours B
M ta Analysis
Meta Analysis
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in perimenopausal women for having depressive symptoms (p < .001). These findings 
confirm the first hypothesis. Further analyses were conducted to more thoroughly 
investigate the data. When comparing pre- and postmenopausal women an odds ratio 
of 1.67 (CI = 1.10, 2.52; p = .015) was found, with postmenopausal women having a 
higher chance of having depressive symptoms. Only in the comparison between 
perimenopausal women and postmenopausal women no significantly increased odds 
ratio was found (p = .072).  
 
 
In evaluating heterogeneity, the I² and the Q indicates high homogeneity among the 
studies that summarize the data that compares peri- and postmenopausal women and 
post- and premenopausal women, this indication was found to be significant based on 
the p-value (p < .05). A moderate heterogeneity was found in the comparison between 
peri-and premenopausal women, however this was not found to be significant.  
Furthermore, Egger’s regression revealed that in none of the analysis a significant 
publication bias was found, tested with a two-tailed p-value.  
 
3.2.3 Depressive symptoms and reproductive stages: Hedge’s g effect size  
By means of a forest plot (figure 4.1 and 4.2) the individual effect sizes of each study 
is displayed. Analyses revealed that perimenopausal women report significantly more 
depressive symptoms (indicating a depression) than premenopausal women with a 
Hedge’s g of 0.22 (p < .001, confirming the second hypothesis. Further analysis 
showed no significant difference between perimenopausal women and 
postmenopausal women in the amount of depressive symptoms. 
Comparisons  k  0R    95% CI  P-value  Q(df)               I ²          p-value 
                
Early-peri vs. pre 2 1.35  (1.15, 1.57) < 0.001  0.006(1) 0.000  0.938 
Late-peri vs. pre 2 1.69  (1.32, 2.18) < 0.001  0.028(1) 0.000  0.866 
Peri vs. pre  7 1.69  (1.28, 2.22) < 0.001  9.035(6) 33.592  0.172 
Peri vs. Post  5 1.68  (0.96, 2.92)     0.072  15.539(4) 74.259  0.004 
Post vs. Pre  6 1.67  (1.10, 2.52)      0.015  14.805(5) 66.228  0.011 
Table 1: analysis of depressive symptoms: odds ratio 
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Figure 4.1 Forest plots of analysis peri- vs. premenopausal women 
  
 
 
 
 
 
 
 
 
Figure 4.4 Forest plots of analysis peri- vs. postmenopausal women 
 
 
 
 
The I² shows no heterogeneity in the comparison between perimenopausal women and 
premenopausal women. However, in the analysis with postmenopausal women as 
reference group a significant heterogeneity was indicated (Q(df)= 20.24 (4); I ² = 
80.24; p < .001). Based on the Egger’s regression test, no publication bias was found 
in these analyses.   
 
 
Comparisons  k  Hedge’s g  95% CI   P-value Q(df)             I ²               p-value 
                 
Peri vs Pre  4 0.22    (0.156, 0.289) < 0.001 1.005(3) 0.000       0.800 
Peri vs Post  5 -0.03    (-0.222, 0.159)       0.73 20.238(4) 80.236   < 0.001       
 
Table 2: analysis of depressive symptoms: Hedge’s g 
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3.3 Results of depression  
3.3.1 Individual studies 
Only two studies where eligible for inclusion to calculate the odds ratio for 
perimenopausal women with a diagnosed depression (Bromberger et al., 2011; Cohen 
et al., 2006). These two longitudinal population-based studies both used 
premenopausal women as reference group and measured a first onset of depression 
based on the Structural Clinical Interview (SCID). Only Bromberger and colleagues 
(2011) compared postmenopausal women to premenopausal. Therefore, the 
comparison between pre- and postmenopausal women was not made in this meta-
analysis. Important to note is that both the included studied reported the odds ratio for 
a first onset depression. Both individual studies reported a heightened chance to have 
a first onset of a major depression in perimenopausal women compared to 
premenopausal women. More specifically, Bromberger (et al., 2011) reported an odds 
ratio of 2,08 (CI = 1.06, - 408) and Cohen and colleagues (2006) reported an odds 
ratio of 1,80 (CI = 1.01, - 3.22). Both study outcomes were found to be significant 
with a p-value of 0.03 and 0.05 respectively.  
 In the study of Bromberger as well as in the study of Cohen the reported data 
was adjusted for vasomotor symptoms (VMS) and history of depression. Due to the 
possible role of VSM in suffering from depressive symptoms (Lu et al., 2009; 
Opperman et al., 2012), another meta-analysis was executed in order to control for 
this confounder. Additionally, other possible confounding factors such as: age, race, 
annual psychotropic medication, annual very upsetting life events, and Body Mass 
Index (BMI), where controlled for.  
 
3.3.2 The relation between the perimenopause and depression 
A significant, almost two times increased odds ratio is found in analysing depression 
in perimenopausal women when compared to premenopausal women (OR = 1.92; CI 
= 1.23, 2.97; p = .004) , confirming the last hypothesis. Important to note is that this 
concerns a first onset depression. The I² suggest that there is no heterogeneity in the 
used studies (Q = 0.10 (1); p = 0.75). In the analysis, no significant publication bias 
has been found based on the Egger’s regression.  
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3.3.3 Results of analysis: the relation between the perimenopause and depression 
adjusted for VMS 
Table 4 shows an increased risk for perimenopausal women to have a diagnosis of 
depression when adjusted for VMS with an odds ratio of 1.88 (CI = 0.99, 3.58). 
However, this outcome is not significant (p = .05), but indicates a trend. The I² shows 
homogeneity between the outcomes of the included studies ( Q(df) = 0.172(1);  I ² = 
<0.001; p-value = .68).   
 
4. Discussion 
The aim of the present study was to clarify the link between perimenopausal women 
and depression. More knowledge regarding this topic will hopefully lead to better 
healthcare and treatment for this group. Based on preliminary research three 
hypotheses were formed. Firstly, it was expected that perimenopausal woman had a 
higher risk of experiencing depressive symptoms than premenopausal women. 
Secondly, perimenopausal women were expected to experience more depressive 
symptoms. Lastly, it was that hypothesized that perimenopausal women are at higher 
risk for depression than premenopausal women.  
Studies included in this meta-analysis used depressive symptom questionnaires and 
structured clinical interviews to assess presence of depression and depression severity. 
 Results indicate that perimenopausal woman had a significantly higher risk of 
having depressive symptoms when compared to premenopausal woman. This finding 
supports the first hypothesis and confirms the results from previous studies that 
perimenopausal women are at higher risk to develop depressive symptoms and a first 
onset depressive episode in comparison to premenopausal women (Almeida et al., 
2014; Cohen et al., 2006; Soares et al., 2001; Dennerstein et al., 2000; Joffe et al., 
2002; Schmidt et al., 2005; Ladd et al., 2005; Harlow et al., 2003). It was also found 
that late perimenopausal woman had a higher risk of having depressive symptoms 
compared to early perimenopausal woman. This suggests that risk differences within 
perimenopausal woman may exist. Possibly, late perimenopausal have had a longer 
period of hormonal fluctuations and perhaps physiological stress, which may result in 
higher risk of depressive symptoms. Therefore, it might be interesting to distinguish 
between early and late perimenopausal periods to further explore the link between this 
group of women and depression. Additionally, compared to premenopausal woman 
both peri- and postmenopausal woman experience significantly more depressive 
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symptoms. Besides, compared to premenopausal women, perimenopausal woman are 
at a significantly increased risk to suffer from a first onset major depression in which 
VMS may play an important role.  
 Furthermore, analyses revealed that perimenopausal women had more 
depressive symptoms than premenopausal women, which confirmed the second 
hypothesis. The found increased risk in perimenopausal women to suffer from 
depressive symptoms and the finding that these women report significantly more 
symptoms than premenopausal women are in line with each other. 
Consequently, women are at high risk to suffer depressive symptoms during the 
menopausal transition. The extent to which they suffer these symptoms can, 
obviously, vary between women.  
 To further explore the relation between depression and the menopausal period, 
postmenopausal women were studied. Data showed an increased risk to suffer from 
depressive symptoms during the postmenopausal stage when compared to 
premenopausal women. No significant difference regarding the risk of having 
depressive symptoms was found between peri- and postmenopausal woman. This 
finding suggests that after the menopause the risk of having depressive symptoms 
stays high. Outcomes of this meta-analysis indicate that postmenopausal women are 
two times more likely to suffer from depressive symptoms indicating a clinical 
depression when compared to pre- and perimenopausal women. Similar outcomes 
were found by a study of Weber and colleagues (2014). Bromberger and colleagues 
(2007) even found depression to be four times more common in postmenopausal 
women when compared to premenopausal women. 
 
 Lastly, it was found that perimenopausal women had a higher risk of being 
diagnosed with a first onset depression compared to premenopausal women. This 
outcome is in line with the last hypothesis. Perimenopausal women are found to be 
almost twice as likely to develop a first onset depression. This result is consistent with 
other studies, such as the longitudinal large-scale study toward the prevalence of 
depressive disorders by Weber and colleagues (2014) and systematic review and 
meta-analysis by Bromberger and colleagues (2007). The advantage of using first 
onset depression in this meta-analysis is that a bias (of measuring a depression in an 
already vulnerable group of women with a history of depression) will be reduced, so 
that the outcomes are more reliable when it comes to investigating the role of the 
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menopausal transition in developing depression. This bias would be present if an 
already psychiatric population was used. 
 In addition, we have analysed the risk of a first onset depression when 
controlled for VMS. This data shows that even when VMS would be absent during 
the menopausal transition a trend is seen of a higher risk during perimenopause with 
premenopausal women as reference group. Important to note is that this outcome is 
not found to be significant when an alpha of .05 is maintained. Arguably, this 
outcome indicates that VMS contributes to the increased risk in developing a first 
onset depression during the perimenopausal stage. This supports the suspected role 
that VMS play in the link between menopause and depression based on earlier 
research, which showed that the risk of being depressed increases 15% for every 
climacteric physiological symptom (Lu et al., 2009). In view of improving healthcare 
for perimenopausal women that suffer from depressive symptoms, it is suggested to 
pay attention to physiological complaints. Indeed, attention for VMS in women could 
possibly prevent the development of depressive symptoms. Further research could 
look into this biological aspect of depression in menopausal woman. 
 In summary it is clearly found that perimenopausal women are more at risk to 
experience depressive symptoms or being diagnosed with a first onset depression 
compared to premenopausal women. Furthermore a difference is found between 
early- and late perimenopausal women, with late-perimenopausal women having a 
higher risk to suffer from depressive symptoms. Postmenopausal women are also 
found to be at high risk to suffer from depressive symptoms when compared to 
premenopausal women. Lastly, no difference was found between peri- and 
postmenopausal women in the risk for having depressive symptoms, while the groups 
are categorized as two different groups by the STRAW criteria. It seems that further 
research is needed to clarify the possible link between postmenopausal women and 
depression and the difference with perimenopausal woman.  
 
4.1 Implications 
The findings of this study confirm the link between the menopause and depression, 
but several questions and implications also arose, which will be elaborated upon in the 
following section.  
Firstly, one of the notable findings of this study was that late-perimenopausal women 
appear to be at a higher risk to have depressive symptoms than early- perimenopausal 
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women, when compared to premenopausal women. This finding requires attention in 
order to have a better understanding of the different sub-stages during the menopausal 
transition.  
Secondly, besides the focus on the perimenopause, the risk to suffer from 
depressive symptoms was also examined in postmenopausal women. An increased 
risk in postmenopausal women to suffer from depressive symptoms was found in 
reference to premenopausal women. In comparison to perimenopausal women, 
postmenopausal women did not show an increased risk to have depressive symptoms. 
These findings suggest that after entering the menopausal transition, during the early-
perimenopause, the risk to suffer from depressive symptoms may increase after which 
the risk continues. However, that the post- menopause is a period of increased risk for 
depressive symptoms is still under debate. Based on our findings we hypothesize 
postmenopausal women to be at an increase risk to have depressive symptoms with 
the early-perimenopause as an important moment of onset for this growing risk. It 
seems interesting to investigate the similarities between peri- and postmenopausal 
women, since both groups are found to be at risk to develop depressive symptoms, 
while being differentiated based on the STRAW criteria. For future research it seems 
valuable to differentiate early-and late, as well as peri- and postmenopausal women to 
get a better understanding of the role of the menopausal transition in depression. 
  An explanation for the increasing number of women suffering from 
depressive symptoms during and after the menopausal transition may be aging. 
Though a previous study conducted among elderly women reported no relation 
between aging and depression (Chrzan et al., 2012), the same study, strangely, 
reported 80% of the 200 included women (aged 75 - 89) to be depressive. 
Nevertheless, another study did report age as an accounting factor in the link between 
the menopause and depression (Woods et al., 2008). The role of age in this topic 
should be further explored.  
 In line with previous speculation, it may also be that longer exposure to 
hormone fluctuations, physical complaints during the menopause (VMS) and periods 
where life-changing events are common might lead to lingering depressive symptoms 
during the menopause and even after this period in postmenopausal women (Borrow 
& Cameron, 2014). However, depression during the menopausal transition has found 
to be strongly linked with VMS while this relation is not found in postmenopausal 
women (Joffe et al., 2002). 
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Alternatively, women might feel reluctant to seek help during or after 
exposure to the perimenopausal period. It is imaginable perimenopausal women feel 
ashamed or view asking for help as negative or weakness, because of the found 
negative attitude towards aging some women report (McKinlay et al., 2008). 
Additionally, preliminary research shows that menopausal woman generally have 
similar problem-related help-seeking behaviors as premenopausal woman (Morse et 
al., 1994). This implies, that despite the found significant increased risk in 
perimenopausal women to have depressive symptoms they do not seek more help 
during this period.  A possible discrepancy might exist between the amount of women 
suffering from depressive symptoms and the number of woman that seek problem-
related help. This may lead to untreated depressive symptoms that last during and 
after the menopause or even worsen and result in a major depression.  
 Important to note is that studies that sampled women attending a clinic were 
excluded from this meta-analysis. Exclusion of women attending a clinic might have 
resulted in the investigation of a group of women that are more reluctant to seek help 
than the entire population. Consequently, the absence of a difference in depressive 
symptoms between peri- and postmenopausal women might be partially explained 
through the relatively high resistance of the sample women to seek help. Untreated 
depressive symptoms may worsen or last and subsist after the menopause in the 
postmenopausal stage. This emphasizes the importance of qualitative and specialized 
health care for perimenopausal and postmenopausal women. 
 
The current findings add to the body of research in this area and help to explain the 
apparent relation between menopausal state and its influence on depression. 
Moreover, this study indicates biological, psychological and social events as 
contributing factors in menopausal women who are vulnerable for depressive 
symptoms or developing a depression. The results of the present study suggest that 
treatment should focus on the mentioned bio-psychosocial factors in order to improve 
the treatment for menopausal women suffering from depressive symptoms. Treatment 
requires a bio-psychosocial approach because the development of depression in 
perimenopausal women is found to be multifactorial based on this study and the 
preliminary literature on this topic. Research suggests a large spectrum of bio-
psychosocial factors to play a role in the vulnerability of menopausal women to suffer 
from depressed mood (Vivian-Taylor & Hickey, 2014). The wide range of facets 
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playing a role in developing a depression during this period indicates the complexity 
of this topic. Research in order to integrate knowledge of these variables in specific 
healthcare for menopausal women seems beneficial in view of the found risk. It is 
suggested to research the specific healthcare-needs of menopausal women in the wide 
range from minor depressive symptoms to a major depression in order to create and 
improve fitting healthcare. Making women conscious of the fact that many women are 
struggling with the same symptoms might give them support and relieve some of the 
confusion and discomfort. Treatment could also focus on the social environment of 
the sufferer. For example, the husband and children could be included in the treatment 
and rehabilitation so that recovery is more quickly and also happens independent of 
the clinic environment. Besides the integrating these social aspects, biological aspects 
of the menopausal transition should be attended in treating depressive symptoms. For 
example VMS has been found to play an important role in the development 
menopausal depressive symptoms, such as night sweats (Dratva et al., 2009). Night 
sweats may lead to a decrease of the quality of sleep, important to note is the 
bidirectional link between depression and sleep disturbances (Vivian-Taylor & 
Hickey, 2014).  
 
Increasing attention is apparent for the role of gender differences in health and the 
medical science. Sex differences stresses the biological as well as the sociological and 
mental base (Wizemann & Pardue, 2001). The current study emphasizes the 
importance of the positive development to differ not only between men and women 
but also within the female population. It seems reasonable to assume that it is 
profitable to distinguish between cohorts because of fundamental differences between 
patient groups, which require specific healthcare adapted to their needs. The current 
findings also help to differentiate between patient groups so that treatments can be 
better individualized. Individualized care is something the Dutch government strives 
to achieve, by providing local and appropriate mental health care for patients with 
mental disorders. To this purpose, the recently developed Dutch policy is 
implemented. This proposed health care transition aims to manage “caring” on a local 
scale. The general practitioner (GP) functions as an important link in referring 
patients to healthcare workers in his or her own practice, namely primary and 
secondary care. Understanding and knowledge about the risk of depression and the 
bio-psychosocial factors involved during the menopausal transition requires attention 
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in the “base healthcare” and by the GP. Accurate diagnostics are important in this 
process, since differentiating between patient populations may deliver a contribution 
to the efficacy and the quality of the treatment process and content, including efficient 
referrals, shorter waiting times and more individualized care. Additionally, this might 
be a cost-effective approach. Despite the fact that the data in this study are not 
necessarily generalizable to the Dutch menopausal women, the outcomes are to be 
taken seriously and could be applied to the Dutch care policy. Indeed, the findings 
underline the importance of differentiating between patient populations, which might 
improve the diagnosing and referral procedure. More specifically, improved 
diagnostics between and within menopausal cohorts might lead to a faster and more 
accurate referral procedure by the GP in the primary care (or other caregiver) and 
shorter waiting for appropriate care. To answer to the need for specific healthcare, the 
secondary care is suggested to offer menopausal women treatment that matches their 
needs in the different facets of this transitional period. In the long run this may reduce 
the amount of women suffering from depressive symptoms and depression or even 
prevent perimenopausal women from developing a depression during and after the 
menopause. This all contributes to the improvement of the Dutch healthcare system 
and quality of life in women overall. 
 
4.2 Limitations 
There are several limitations to this study. Firstly, a limited number of studies were 
eligible for inclusion, which led to a small number of studies to analyse. This was 
probably the most important limitation. The reported results only apply to the studies 
that were included in this meta-analysis and they cannot necessarily be generalized. 
Much relevant information is lost by inadequate data reports or studies maintaining 
doubtful inclusion criteria. In this process we have contacted authors in order to 
collect missing data and to ensure reliable analyses. However, this led to no results. 
The current outcomes are likely influenced by the inability to include all relevant 
studies based on our maintained criteria to define perimenopausal women and 
measuring depressive symptoms and depression. For example four (Bromberger et al., 
2009; Chen et al., 2013; Bromberger et al., 2011; Cohen et al., 2006) studies met the 
inclusion criteria for measuring the risk for depression in perimenopausal women 
while only two studies where eligible for inclusion (Bromberger et al., 2011; Cohen et 
al., 2006). Consequently, when only limited studies are included this may lead to low 
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power of the test results. However, it is found that increasing the number of studies in 
a meta-analysis using Random-Effect analysis does not always increase statistical 
power (Cohn & Becker, 2003). Moreover, strictly selecting studies, leads to reduction 
in differences among studies, and contributed to a more specified outcome. This 
improves data quality and thus enhances the interpretation, reliability and validity of 
the results. In addition, no publication bias has been found in this meta-analysis. In 
conclusion, although some relevant information may not be implemented in this 
study, there seems no indication for a selection bias and publication bias in the test 
results. 
 Only in the data that summarized depressive symptoms in pre- and 
perimenopausal women in comparison to postmenopausal women, high heterogeneity 
was indicated. While using the RE model, what already takes possible heterogeneity 
into account, it is important not to underestimate the possible role of the found 
heterogeneity. Heterogeneity is a common pitfall in meta-analysis, however it also 
may offer opportunity for insight when moderating variables can be detected that 
explain or partly clarify, some of the variability between the studies (Cumming, 
2012). The found heterogeneity may be due to the small number of studies included. 
Another possible explanation may be that origin plays a role; the included studies 
vary widely in the countries in which the studies are conducted, this may have 
contributed to the variability in the data. Because of the strictly maintained inclusion 
criteria that where used, and the comparable populations and calculated effect sizes 
the found heterogeneity is not fully explained and may be interesting for future 
research. 
 Secondly, the selected population may reduce the generalizability of the study 
and therefore possibly raise threats to external validity. Only healthy women can be 
identified in the STRAW system, so many women where excluded from the used 
studies. This led to exclusion of a large part of the overall population and possibly an 
impact on the results of the studies as well as on the study outcomes. Additionally, 
women attending a clinic where excluded from this study. Consequently, exclusion of 
healthy women may have had consequences for the test results. It is possible that the 
risk to suffer from depressive symptoms would be higher when non-naturally 
menopausal women and women attending a clinic were included. Research conducted 
among women attending a menopause clinic in California showed that 63% had a 
significant depression and 79% presented severe physical symptoms such as VMS 
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(Anderson et al., 1987). These menopausal help-seeking women are not represented in 
this study, which may have had an influence on our outcomes.   
 Lastly, STRAW defined women may be included in the perimenopausal group 
based on self-report while the possibility exists that she is already postmenopausal. 
Because of the continuing reproductive aging in women it is imaginable that they are 
not included in the right group. However, the STRAW criteria help to prevent this 
pitfall, since they are strictly maintained.  
  
4.3 Future Research 
Future research could focus on the distinguishing between early and late 
perimenopausal women and the link to depression. Since the present study found a 
trend for a higher risk in early perimenopausal women compared to late 
perimenopausal women, it seems interesting to further investigate this relation. More 
knowledge about the perimenopausal stages would be valuable, because treatment 
could then be further individualized for women in the menopausal transition.  
Future research might also consider the difference between perimenopausal 
and postmenopausal women. It seems contradicting that these groups are segregated 
by the widely used STRAW criteria, while the risk for depression or depressive 
symptoms are similar and seems to last after the menopausal transition. The hormonal 
levels are different in these two cohorts (Harlow et al., 2012), so other factors, such as 
life events attitudes toward ageing, should also be taken into account when exploring 
factors that induce depressed mood. It might be interesting to conduct research 
towards peri- and postmenopausal women to clarify the found differences and 
similarities between these subgroups. A more thorough understanding could 
eventually lead to better diagnostic procedures and more efficient healthcare.  
Further suggestions for research could be to investigate the help seeking 
behaviour is in perimenopausal- and postmenopausal women because in order to 
clarify a possible discrepancy between suffering from depressive symptoms and help-
seeking behaviour.  
Finally, other research could take a closer look at specific biological changes, 
psychological symptoms or complaints that women in the perimenopausal period find 
especially burdensome or which are strong predictors of depression. Perhaps this will 
give a clearer indication of how, when and where to start treatment. 
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4.4 Conclusion 
This meta-analysis has confirmed the expectations that the menopausal transition is a 
period for women when they are vulnerable to develop depressive symptoms. This 
meta-analysis adds body to the research of the link between reproductive aging and 
depression, with the menopausal transition as a significant stage. Perimenopausal 
women are found to be at a significant higher risk to suffer from a first onset 
depression. Notable is the role of VMS that possibly contribute to depressive 
symptoms in menopausal women. Postmenopausal are also found to be more 
vulnerable to suffer from depressive symptoms than premenopausal women. 
Therefore, entering the menopausal transition is an important moment in a women’s 
life and carries vulnerability to depressive symptoms. Despite limitations the study 
results should be taken seriously and show that a bio-psychosocial approach to the 
problems would be most appropriate because of the wide range of contributing 
factors. Future research could focus on differentiating stages during reproductive 
aging, which may contribute to a better diagnostic system and may lead to appropriate 
and individualized healthcare. Additionally, knowledge and awareness may lead to 
early recognition of depressive symptoms and may reduce the number of menopausal 
and postmenopausal women suffering from depression. In conclusion, attention for 
women in the menopausal transition seems appropriate, since the risk of these women 
to experience sadness and depression seems high indeed. 
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